Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a report released on Wednesday morning. The brokerage issued a hold rating on the medical research company’s stock.

Separately, BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

Accelerate Diagnostics Stock Down 0.8 %

Shares of NASDAQ:AXDX opened at $1.26 on Wednesday. The business’s 50 day moving average is $1.25 and its 200 day moving average is $1.54. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $2.09. The stock has a market cap of $31.55 million, a price-to-earnings ratio of -0.44 and a beta of 0.61.

Insider Transactions at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience bought 200,000 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average cost of $1.57 per share, for a total transaction of $314,000.00. Following the purchase, the director now directly owns 653,224 shares of the company’s stock, valued at approximately $1,025,561.68. This trade represents a 44.13 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 43.60% of the company’s stock.

Institutional Trading of Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd bought a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned about 0.08% of Accelerate Diagnostics as of its most recent SEC filing. 17.14% of the stock is owned by institutional investors and hedge funds.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.